** Brokerage Stifel resumes coverage on drug developer Soleno Therapeutics SLNO.O with a "buy" rating and a PT of $74
** SLNO's experimental rare-disease drug DCCR has an 80% chance of an FDA approval for the treatment of a rare genetic disorder known as Prader-Willi syndrome - brokerage
** Prader-Willi syndrome affects parts of the body with constant hunger, cognitive impairment and behavioral issues
** Brokerage believes that the FDA will be flexible in the approval process, given the significant unmet need for this rare disease
** We expect sales exceeding $1.5 billion, given that the loss of exclusivity is not expected until the mid-2030s - Stifel
** "We model a blockbuster opportunity that implies meaningful potential upside to the stock. We also think M&A is likely a plausible upside case as well" - Stifel analysts
** Stock down 5% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.